Please login to the form below

Not currently logged in
Email:
Password:

Amgen set for Kyprolis label boost after CHMP backing

Multiple myeloma treatment set to add new survival data

Amgen

The Committee for Medicinal Products for Human Use (CHMP) has given the go-ahead for Amgen to add survival data to the labelling for its multiple myeloma treatment Kyprolis (carfilzomib).

Kyprolis, which was initially approved in the EU two years ago after a few missteps, was recently investigated in a phase III trial that pitted the drug against Takeda’s Velcade (boretezomib).

The move was a bit dicey considering Kyprolis’ last head-to-head trial with the proteasome inhibitor in 2016 saw it fail to demonstrate superior progression-free survival.

This time around both Kyprolis and Velcade were studied in combination with dexamethasone, and results demonstrated that Kyprolis reduced the risk of death by 21% and increased overall survival by 7.6 months verses Velcade in patients with relapsed or refractory multiple myeloma.

David Reese, senior vice president of translational sciences and oncology at Amgen, said: “The positive opinion issued by the CHMP underscores our commitment to helping patients live better, longer lives.”

Currently, Kyprolis is approved in the EU for us in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.

The disease itself is as a rare, incurable blood cancer, characterised by the recurring pattern of remission and relapse and accounting for one percent of all cancers.

According to Globocan, a project for cancer research, approximately 39,000 patients are diagnosed with multiple myeloma each year, and around 24,000 patient deaths are reported on an annual basis.

Reese added: “We’re proud to share these results with European regulatory authorities and believe Kyprolis is advancing the standard of care for patients with relapsed or refractory multiple myeloma.”

Article by
Gemma Jones

1st February 2018

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics